Universidad Autónoma de Madrid-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2015

  1. Plasma Concentrations of BDNF and IGF-1 in abstinent cocaine users with high prevalence of substance use disorders: Relationship to psychiatric comorbidity

    PLoS ONE, Vol. 10, Núm. 3

2011

  1. Fenofibrate, a PPARα agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy

    American Journal of Physiology - Endocrinology and Metabolism, Vol. 300, Núm. 5

2000

  1. Maternal exposure to the synthetic cannabinoid HU-210: Effects on the endocrine and immune systems of the adult male offspring

    NeuroImmunoModulation, Vol. 7, Núm. 1, pp. 16-26

1998

  1. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats

    NeuroReport, Vol. 9, Núm. 15, pp. 3397-3402

  2. Characterization of the acute endocrine actions of (-)-11-hydroxy-Δ8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats

    European Journal of Pharmacology, Vol. 344, Núm. 1, pp. 77-86

1997

  1. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat

    NeuroReport, Vol. 8, Núm. 2, pp. 491-496

1995

  1. Cyclosporine Effects on in vitro Responsiveness of Anterior Pituitary Hormone Release to Dopamine and Thyrotropin‐Releasing Hormone in Young Female Rats

    Journal of Neuroendocrinology, Vol. 7, Núm. 10, pp. 765-774

1989

  1. Possible prolactin-mediated effects of melatonin on gonadotropin secretion in the rat

    Pharmacology, Biochemistry and Behavior, Vol. 32, Núm. 1, pp. 157-162